<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962673</url>
  </required_header>
  <id_info>
    <org_study_id>H17-00303</org_study_id>
    <nct_id>NCT03962673</nct_id>
  </id_info>
  <brief_title>UVB: Skin to Gut Study</brief_title>
  <official_title>Intestinal Microbiota Changes After Ultra Violet Radiation B Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will explore the potential effects of Narrow-Band Ultra Violet B (NB-UVB)
      radiation on the intestinal microbiota composition and confirm a regulatory skin-to-gut axis
      during baseline conditions. Changes in the intestinal microbiota composition caused by NB-UVB
      phototherapy could be beneficial for patients with chronic/auto-inflammatory diseases like
      inflammatory bowel disease (IBD) by removing dangerous bacteria, increasing beneficial
      bacteria, and ultimately modulating immune responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      To explore the potential effects of Narrow-Band Ultra Violet B (NB-UVB) radiation on the
      intestinal microbiota composition in humans and confirm a regulatory skin-to-gut axis during
      baseline conditions.

      Hypothesis:

      Humans exposed to UVB-NB light will show changes in the intestinal microbiota composition
      with the selection of certain phyla of bacteria.

      Justification:

      To date, there is no data that describes a biological response to UVB light in the body that
      affects the intestinal microbiota. Changes in the intestinal microbiota composition caused by
      NB-UVB phototherapy could be beneficial for patients with chronic/auto-inflammatory diseases
      like IBD by removing dangerous bacteria, increasing beneficial bacteria, and ultimately
      modulating immune responses.

      Objectives:

        1. Establish if there is a skin regulatory response towards NB-UVB light in humans.

        2. Examine what changes in the microbiota composition can be observed on bacterial phyla
           and class level.

        3. Determine if this research is worth pursuing in a larger cohort.

      Research design:

      During the first visit, the skin type will be assessed by using the Fitzpatrick skin type
      questionnaire.

      Subsequently, subjects will be exposed three times within one week to full body NB-UVB light
      in The Skin Care Centre to a sub erythemic dose (cause slight redness of the skin but not
      burning). The exposures will happen during the winter months to prevent UVB exposure from the
      sun during daily activities to interfere with our observations. Stool samples will be
      collected before the first exposure (2x) and after the last exposure (2x) to analyze the
      microbiota composition. Also, serum vitamin D (25-hydroxy vitamin D) will be measured before
      and after the UVB exposure as a marker of previous UVB exposure before the experiment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants are receiving the same treatment of which the UVB dose is adjusted for the participants Fitzpatrick skin type.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum vitamin D</measure>
    <time_frame>1 week</time_frame>
    <description>The effect of UVB light exposures on the serum vitamin D concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiome</measure>
    <time_frame>Before and after the UVB exposures (1 week apart)</time_frame>
    <description>Changes in the fecal microbiome composition after the UVB light exposures</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>UVB- exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>NB-UVB light exposure</intervention_name>
    <description>Participants are exposed to three low dose Narrow Band UVB light.</description>
    <arm_group_label>UVB- exposure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian females

          -  Fitzpatrick skin type I, II or III

        Exclusion Criteria:

          -  Skin photosensitivity due to medication

          -  Been on vacation to a sunny destination three months before enrollment

          -  Visit tanning beds on a regular basis in the past
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy Caucasian females</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A. Vallance, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BC Childrens Hospital Research institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Childrens Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Bruce Vallance</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Phototherapy</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Vitamin D</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participant information remains deidentified.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03962673/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

